title: [Intravenous ferric carboxymaltose-associated hypophosphatemia in patients with iron deficiency anemia. A common side effect].
abstract: OBJECTIVE
  To determine the frequency, severity, time of onset and factors associated with the development of hypophosphatemia (HF) in patients with iron deficiency anemia treated with intravenous ferric carboxymatose (ivFCM).
  
  
  METHODS
  Retrospective cohort study in patients iron deficiency anemia who received ivFCM and had an a prior and subsequent determination of serum phosphate. We carried out a comparative analysis between baseline and post-ivFCM levels of serum phosphate. In order to identify variables independently associated with HF a logistic regression analysis was also performed.
  
  
  RESULTS
  One hundred twenty-five patients were included. HF frequency was 58%. The median time to onset of HF was 18 days. Age, baseline ferritin levels and baseline phosphate levels were independently associated with the development of HF. The risk of HF in patients with baseline phosphate levels ≤ 3.1mg/dl was 67% higher than patients with ≥ 3.7 mg/dl.
  
  
  CONCLUSIONS
  ivFCM-associated HF is a frequent, early and, sometimes, prolonged effect in patients with iron deficiency anemia. Serum phosphate levels should be monitored after ivFCM administration, especially in older patients and in those with lower baseline phosphate or ferritin levels.
authors.affiliation: Servicio de Medicina Interna, Complejo Asistencial Universitario de Salamanca, Salamanca, España.
authors.forename: Rebeca
authors.initials: R
authors.lastname: Sánchez González
authors.affiliation: Servicio de Medicina Interna, Complejo Asistencial Universitario de Salamanca, Salamanca, España. Electronic address: hgternavasio@saludcastillayleon.es.
authors.forename: Hugo Guillermo
authors.initials: HG
authors.lastname: Ternavasio-de la Vega
authors.affiliation: Unidad y Consulta de Atención Inmediata (UCAI), Servicio de Medicina Interna, Complejo Asistencial Universitario de Salamanca, Salamanca, España.
authors.forename: Leticia
authors.initials: L
authors.lastname: Moralejo Alonso
authors.affiliation: Unidad y Consulta de Atención Inmediata (UCAI), Servicio de Medicina Interna, Complejo Asistencial Universitario de Salamanca, Salamanca, España.
authors.forename: Sandra
authors.initials: S
authors.lastname: Inés Revuelta
authors.affiliation: Unidad y Consulta de Atención Inmediata (UCAI), Servicio de Medicina Interna, Complejo Asistencial Universitario de Salamanca, Salamanca, España.
authors.forename: Aurelio
authors.initials: A
authors.lastname: Fuertes Martín
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018798:Anemia, Iron-Deficiency / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005290:Ferric Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D006397:Hematinics / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D017674:Hypophosphatemia / Q000139:chemically induced* / Q000175:diagnosis; D007262:Infusions, Intravenous; D016015:Logistic Models; D008297:Male; D008320:Maltose / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D005290:Ferric Compounds; D006397:Hematinics; C522335:ferric carboxymaltose; D008320:Maltose
keywords: Anemia ferropénica; Ferric carboxymaltose; Hierro carboximaltosa; Hipofosfatemia.; Hypophosphatemia; Iron deficiency anemia